Topiramate Tablet
Product Images NDC 31722-182

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 31722-182). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tab1 (Tab1)

A table presenting the monotherapy titration schedule for adults and pediatric patients aged 10 years and older, showing morning and evening doses of the medication across six weeks, with dosages increasing from 25 mg to 200 mg.*

FDA Label Image

Tab2 (Tab2)

A table showing monotherapy target total daily maintenance dosing for patients aged 2 to 9 years based on weight in kilograms. It lists minimum and maximum daily doses in mg/day, administered in two equally divided doses, for weight ranges up to greater than 38 kg.*

FDA Label Image

Tab3 (Tab3)

A table titled Preventive Treatment of Migraine Titration Schedule for Patients 12 Years of Age and Older, showing weekly dosage increments of Topiramate over four weeks with specified morning and evening doses ranging from none to 50 mg.*

FDA Label Image

Tab4 (Tab4)

A data table titled 'Risk by Indication for Antiepileptic Drugs in the Pooled Analysis.' It presents risk metrics including events per 1000 patients with Placebo and with drug treatment, relative risk comparing drug versus placebo patients, and risk difference, categorized by indication groups: Epilepsy, Psychiatric, Other, and Total.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of the active ingredient Topiramate, showing its molecular components and bonds as part of the pharmaceutical product TOPIRAMATE by Camber Pharmaceuticals, Inc.*

FDA Label Image

Figure1 (Figure 1)

A cumulative rate curve graph showing time to first seizure over 500 days. Two curves represent Topiramate 50 mg/day (N=234) and 400 mg/day (N=236). The y-axis shows cumulative rates for time to first seizure, and the x-axis shows time in days. A p-value of 0.0002 is displayed, indicating statistical comparison.*

FDA Label Image

Tab12 (Table 12)

Table showing topiramate dose summaries during stabilization periods of six double-blind, placebo-controlled trials in adults with partial-onset seizures. The table lists study numbers, stabilization dose (N, mean dose, median dose), placebo tablet counts, and target topiramate dosages ranging from 200 mg/day to 1000 mg/day.*

FDA Label Image

Tab13 (Table 13)

A data table titled 'Efficacy Results in Double-Blind, Placebo-Controlled, Adjunctive Epilepsy Trials' presenting median percentage reductions and percentages of responders across various studies of Topiramate dosage levels (placebo to 1,000 mg/day). Results are divided into Partial-Onset Seizures in Adults, Partial-Onset Seizures in Pediatric Patients, Primary Generalized Tonic-Clonic, and Lennox-Gastaut Syndrome categories.*

FDA Label Image

Tab14 (Table 14)

Data table showing the percent reduction from baseline to the last 12 weeks of the double-blind phase in average monthly attack rate for Placebo, Topiramate 50 mg/day, and Topiramate 100 mg/day groups in Study 13 (Intent-to-Treat Analysis Set). It includes median values for baseline, last 12 weeks, and percent reduction, with P-values comparing treatments to placebo.*

FDA Label Image

Figure2 (Figure 2)

A bar graph comparing change from baseline in double-blind phase average monthly migraine period rate (± SEM) for placebo and Topiramate doses 50 mg/day, 100 mg/day, and 200 mg/day across two studies (Study 11 and Study 12). The graph shows decreasing migraine rates with increasing Topiramate doses, with statistical significance indicated for 100 mg/day and 200 mg/day doses.*

FDA Label Image

Mg1 (Mg1)

A text panel listing side effects associated with Topiramate tablets. Side effects include feeling tired, loss of appetite, changes in heartbeat, and trouble thinking clearly. The panel provides bullet points summarizing these symptoms without additional context or instructions.*

FDA Label Image

Mg2 (Mg2)

A text panel listing various behavioral and mood-related side effects such as thoughts about suicide, attempts to commit suicide, new or worsening depression, anxiety, agitation, panic attacks, insomnia, irritability, aggressive or violent behavior, dangerous impulses, mania, and unusual changes in behavior or mood.*

FDA Label Image

Mg3 (Mg3)

A list of side effects associated with a medication, including tingling of the arms and legs (paresthesia), nervousness, slow reactions, nausea, upper respiratory tract infection, speech problems, difficulty with memory, changes in taste perception, tiredness, pain in the abdomen, diarrhea, dizziness, fever, weight loss, sleepiness/drowsiness, abnormal vision, and decreased feeling or sensitivity, especially in the skin.*

FDA Label Image

25 mg-60 (25 mg 60s)

The label for Topiramate Tablets, USP 25 mg by Camber Pharmaceuticals, Inc. Displays the NDC 31722-181-60 and indicates a 60 tablet count. Includes dosage strength (25 mg), dispensing cautions, storage instructions, and manufacturer information. Also notes prescription-only status and child-resistant packaging requirements.*

FDA Label Image

25 mg-500 (25 mg 500s)

Label of Topiramate Tablets USP 25 mg by Camber Pharmaceuticals, Inc. The tablet bottle label states a quantity of 500 tablets and includes the NDC code 31722-181-05. Dosage instructions advise verifying prescription before dispensing and refer to accompanying product literature. Storage conditions and manufacturer details are provided on the right side of the label.*

FDA Label Image

50 mg-60 (50 mg 60s)

Topiramate 50 mg tablets label from Camber Pharmaceuticals, Inc. The label includes the proprietary name Topiramate, strength 50 mg, dosage form tablets USP, and prescription use (Rx only). It indicates the package contains 60 tablets and includes storage, dispensing, and safety instructions, along with manufacturer details for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc.*

FDA Label Image

50 mg-500 (50 mg 500s)

Topiramate Tablets, USP 50 mg oral tablets label from Camber Pharmaceuticals, Inc. The label highlights a 500 tablet count, includes cautionary dispensing instructions, and provides storage and handling information. Manufactured by Ascent Pharmaceuticals, Inc. and for Camber Pharmaceuticals, Inc.*

FDA Label Image

100 mg-60 (100 mg 60s)

Topiramate Tablets USP 100 mg oral tablets label from Camber Pharmaceuticals, Inc. The label indicates 60 tablets per container, prescription only (Rx only), and includes handling instructions such as dosage verification by the pharmacist, storage conditions, and cautions to keep out of reach of children. The label also provides manufacturer information and directs users to additional medication guides online.*

FDA Label Image

100 mg-500 (100 mg 500s)

Topiramate Tablets USP 100 mg bottle label from Camber Pharmaceuticals, Inc. The label includes the NDC 31722-183-05 and indicates the package contains 500 tablets. Instructions for storage, prescription verification, pharmacist dispensing, and product manufacturing details are also shown.*

FDA Label Image

200 mg-60 (200 mg 60s)

Topiramate Tablets USP 200 mg oral tablets label from Camber Pharmaceuticals, Inc. The label indicates a package of 60 tablets, prescription only. It includes instructions for storage, caution to verify prescription before dispensing, and manufacturer details for Ascent Pharmaceuticals, Inc. and Camber Pharmaceuticals, Inc. The label highlights no varnish coating and includes a barcode and NDC 31722-184-60.*

FDA Label Image

200 mg-500 (200 mg 500s)

Topiramate Tablets, USP 200 mg oral tablets packaging label from Camber Pharmaceuticals, Inc. The label features the NDC 31722-184-05, states a quantity of 500 tablets, and includes usage cautions, storage instructions, and manufacturer details. The label instructs to verify prescription before dispensing and references a medication guide online.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.